Tests SHR-7787 with adebrelimab for limited-stage small cell lung cancer
Tests SHR-7787 with adebrelimab in adults with limited-stage small cell lung cancer.
Plain-language title generated from the registry record
Registry title: A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC
Key facts
- Where
- Jinan, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with limited-stage small cell lung cancer that cannot be removed by surgery and has not grown after platinum-based chemotherapy and radiation.
- Age
- 18 to 75 years
- Sex
- Any gender
- Disease stage
- Limited-stage small cell lung cancer that cannot be removed by surgery, confirmed by tissue or cell tests. The disease has not progressed after platinum-based chemotherapy and radiation therapy.
- Earlier treatment
- Must have had platinum-based chemotherapy and radiation therapy. Must not have had immune checkpoint inhibitors before.
Main reasons for not taking part
- Combined or transformed small cell lung cancer
- Another cancer within the last 5 years
- Prior treatment with immune checkpoint inhibitors
- Active, known or suspected autoimmune disease, or a history of it
- Malignant fluid around the lung or heart
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07798947, who can take part
Where in China
- Cancer Hospital of Shandong First Medical UniversityJinan, ChinaContact: Jinming YuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Trial code
- NCT07798947
- Record updated
- 19 October 2026
- Original description
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung cancer.Read full original descriptionShow less
A Multicenter, Open-label, Phase Ⅱ Clinical Study of SHR-7787 Injection Combined With Adebrelimab in Patients With Limited Stage Small Cell Lung Cancer
This study is an open-label, multicenter, phase II clinical study designed to evaluate the preliminary efficacy, safety, and tolerability of SHR-7787 in combination with Adebrelimab in patients with limited-stage small cell lung cancer.
Inclusion: Voluntarily participate in this clinical study, understand the study procedures, and be able to sign the informed consent form (ICF) in writing; Aged 18 to 75 years (inclusive), of any gender; Histologically or cytologically confirmed unresectable limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemotherapy and radiation therapy; ECOG performance status score of 0 or 1; Estimated survival time of more than 3 months; Have adequate bone marrow and organ function; Female trial participants of childbearing potential must agree to use highly effective contraception from the time of signing the informed consent form until 6 months after the last dose of the investigational drug, and avoid donating eggs.
Exclusion: Bleeding symptoms of significant clinical relevance within 3 months prior to the first dose of the study drug; Severe infection within 4 weeks prior to the initiation of study treatment; Active tuberculosis infection within 1 year prior to enrollment, identified by medical history or imaging examination; Prior treatment with immune checkpoint inhibitors (ICIs); Undergone major organ surgery within 4 weeks prior to the first dose of the study drug; Combined small cell lung cancer or any transformed small cell lung cancer; History of other malignancies within 5 years prior to the first dose of the study drug; Severe cardiovascular or cerebrovascular diseases; Malignant pleural effusion or malignant pericardial effusion; History of immunodeficiency; Active, known, or suspected autoimmune disease, or a history of autoimmune disease; Any other factors that, in the judgment of the investigator, may affect the study results or force premature termination of the study.